Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report - Qian, Bing; Leng, Wenshu; Yan, Zhengqing; Lu, Jin; Chen, Shiqing; Yi, Huan; Jiang, Zhi (Frontiers in Oncology, 2022)